Regeneron and Sanofi announce FDA approval of DUPIXENT(R) (dupilumab)
Regeneron and Sanofi announced the FDA approved DUPIXENT® (dupilumab) Injection, the first and only biologic medicine approved for treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies. March 28, 2017